Introduction
Brequinar is a novel antimetabolite that interferes with dihydrooratate dehydrogenase, an enzyme crucial for pyrimidine biosynthesis [4] . Brequinar was selected for clinical development because of its broad antitumor activity in murine models (L1210 leukemia and B 16 melanoma) and human tumor xenografts [breast (MX-1), colon (CX-1), lung (LX-1), and gastric (BL/STX-1)] [7] .
A number of phase I studies using different dose levels and schedules have been reported [1-3, 5, 8, 9] . In these phase I studies, the dose-limiting toxicities included thrombocytopenia and mucositis/stomatitis. On the basis of the phase I experience, the recommended phase II starting dose of brequinar on the weekly intravenous schedule was 1,800 mg/m 2 [2, 3] . However, early in the phase II evaluation of brequinar in several tumor categories, this starting dose resulted in unacceptable toxicity [6] . As a result, the starting dose was reduced to 1,200 mg/m2 weekly. This multicenter study was designed to evaluate the activity of brequinar in patients with advanced nonsmall-cell (NSC) and small-cell (SC) lung cancer.
Patients and methods
NSC patients were chemotherapy-naive and SC patients had received at most one prior chemotherapy regimen. Additional criteria for inclusion in the study were a performance status of --<2 (WHO scale), a life expectancy of >8 weeks, a serum bilirubin level of <1.5 mg/dl, a serum creatinine value of <2.0 mg/dl, an absolute granulocyte count of >1,500 cells/mm 3, a platelet count of >100,000/mm 3, and the presence of bidimensionally measurable disease. Informed consent was given by all patients in accordance with regulatory agency requirements.
Brequinar was given intravenously once weekly at a starting dose of 1,800 (3 patients) or 1,200 mg/m 2 (50 patients) in 500 ml normal saline over 1-2 h. The subsequent dose of brequinar was escalated or decreased by a fixed amount as specified in the protocol according to predetermined criteria and depending on the toxicities experienced in the preceding course. When necessary, dosing was delayed until the patient had recovered from toxicities. Toxicity was coded by NCI common toxicity criteria (2/18/88 versions.
Patients were interviewed and examined prior to each dose of chemotherapy. Laboratory studies including complete blood cell. differential, and platelet counts were repeated once a week. Total protein, albumin, calcium, inorganic phosphorous, glucose, blood urea nitrogen, creatinine, uric acid, total bilirubin, alkaline phosphatase, lactic dehydrogenase (LDH), and electrolytes were assessed every 4 weeks.
Response was evaluated every 4 weeks by appropriate radiology studies and clinical measurement of bidimensional lesions. Criteria for defining response were standard except that a palpable reduction in liver size was not used to designate a partial response [10] . Patients were considered to be evaluable for response if they received at least one dose of brequinar and underwent a subsequent assessment of their measurable 
Results
From January 1989 to July 1990, 53 patients with histologically or cytologically documented, advanced, measurable carcinoma of the lung were entered in the study. Table 2 . The 53 patients received 343 doses of brequinar (median, 5; range, 1-24). In 11 patients dose escalation was possible, and in 17 patients dose reduction was required; 3 patients received oniy 1 dose. The median weekly dose was 1,200 rag/m2. Of the 53 patients, 49 were evaluable for response. Two patients were deemed ineligible: one due to the absence of a measurable lesion and the other due to a history of prior malignancy. In addition, two patients were inevaluable due to early non-disease-related death and inability to obtain follow-up tumor measurements. PRs were observed in one NSC and two SC patients.
All 53 patients were evaluable for toxicity. In general, the toxicity encountered in this phase II trial was moderate. The major nonhematologic and hematologic toxicities encountered are listed in Table 3 . There was no treatment-related death. In all, 13 episodes of grade 4 toxicity occurred in 8 (15%) patients (NSC, 3; SC, 5). In one NSC patient the grade 4 toxicity was associated with the 1,800-mg/m 2 starting dose; the remaining instances of grade 4 toxicity occurred in patients whose starting dose was 1,200 mg/m 2 and generally occurred during the early treatment doses. Seven patients experienced grade 4 thrombocytopenia. Five of these patients received platelet transfusions and four showed evidence of bleeding; however, in only two patients was the bleeding sufficient to require replacement. The grade 3 toxicities summarized in Table 3 occurred in 11 (21%) patients (NSC, 8; SC, 3). In two NSC patients who experienced grade 3 toxicity the starting dose was 1,800 mg/m2; the remaining grade 3 toxicities occurred in patients whose starting dose was 1,200 mg/m 2.
Grade 3-4 toxicity was observed in all three patients entered at the initial starting dose of 1,800 mg/m 2. The reduction in the starting dose to 1,200 mg/m2 resulted in a more acceptable level of grade 3-4 toxicity (16/50 patients, 32%). Dose escalation was possible in 21% (11/53) of patients; however, despite the reduction in the starting dose, a further dose reduction was required at some point in the course of treatment in 32% (17/53) of patients. The reduction in the starting dose followed by additional escalations and reductions based on individual patient tolerance account for the wide range (740-2,986 rag/m2) of weekly doses given to these patients with lung cancer. The dose given to SC patients was escalated less frequently than that given to NSC patients, and the SC patients required dose reduction more frequently. This variation in tolerance may in part reflect the greater hepatic involvement in the SC patient group as well as their prior exposure to chemotherapy.
Discussion
The response rate of 5% (one-sided 95% confidence limit, 26%) obtained in NSC lung cancer and that of 6% (onesided 95% confidence limit, 20%) obtained in SC lung cancer are disappointing. On the basis of these results, we conclude that at this dose and on this schedule, brequinar sodium does not have sufficient activity to warrant further evaluation in patients with advanced NSC or previously treated SC lung cancer. However, since responses were observed in previously treated SC lung-cancer patients, further evaluation in chemotherapy-naive patients may be warranted.
